In-silico Studies of Heterocyclic Benzoxazole Derivatives as an Anticancer Agent: Molecular Docking, 2D and 3D QSAR

In-silico molecular docking studies and QSAR study of benzoxazole derivatives synthesized by Kakkar et al. was done. Comparative studies of docking of 5-flurouracil and 20 compounds revealed presence of considerable interactions which indicates the affinity of newly synthesized compounds for thymidy...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of pharmaceutical sciences and drug research pp. 780 - 788
Main Authors Pawar, Smita J., Zope, Dhanashri, Kale, Amol P.
Format Journal Article
LanguageEnglish
Published 30.11.2023
Online AccessGet full text

Cover

Loading…
More Information
Summary:In-silico molecular docking studies and QSAR study of benzoxazole derivatives synthesized by Kakkar et al. was done. Comparative studies of docking of 5-flurouracil and 20 compounds revealed presence of considerable interactions which indicates the affinity of newly synthesized compounds for thymidylate synthase. The statistically significant 2D-QSAR models were developed using molecular design suite (VLifeMDS 4.6). The study was performed with 20 compounds (data set) using sphere exclusion (SE) algorithm, random selection and manual selection methods used for the division of the data set into training and test set. Multiple linear regression [MLR] methodology with stepwise (SW) forward-backward variable selection method was used for building the QSAR models. The results of the 2D-QSAR models were further compared with 3D-QSAR models generated by kNN-MFA, (k-Nearest Neighbor Molecular Field Analysis) investigating the substitutional requirements for the favourable anticancer activity against HCT 116 cell line and providing useful information in the characterization and differentiation of their binding sites. The results derived may be useful for further designing of benzoxazole derivatives as anticancer agents prior to synthesis.
ISSN:0975-248X
0975-248X
DOI:10.25004/IJPSDR.2023.150612